Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
Open Access
- 13 May 2024
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 193, 107821
Abstract
No abstract availableKeywords
Funding Information
- Regeneron Pharmaceuticals Inc
- Sanofi US
This publication has 17 references indexed in Scilit:
- Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3Cancer, 2023
- Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?Clinical Lung Cancer, 2023
- Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 TrialJournal of Thoracic Oncology, 2023
- Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival BenefitJournal of Thoracic Oncology, 2022
- Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysisESMO Open, 2022
- Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189Annals of Oncology, 2021
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trialThe Lancet, 2021
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancerEuropean Journal of Cancer, 2019
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectJournal of Thoracic Oncology, 2018
- Signatures of mutational processes in human cancerNature, 2013